Dr Alasdair Henderson

  • Research Scientist - Lead Biostatistician (Cardiovascular & Metabolic Health)

email: Alasdair.Henderson@glasgow.ac.uk

BHF Cardiovascular Research Centre, 126 University Place, Glasgow, G12 8TA

Import to contacts

ORCID iDhttps://orcid.org/0000-0002-8903-4906

Biography

Alasdair Henderson is a biostatistician and epidemiologist working in the School of Cardiovascular and Metabolic Health at the University of Glasgow with a particular focus on heart failure. Since joining the University of Glasgow in 2023, Alasdair has led and supported analyses of large datasets from clinical trials of established heart failure, primarily the analysis of the FINEARTS-HF (NCT04435626). He uses R and Stata to apply frequentist and Bayesian analysis techniques to answer research questions.

Alasdair has previously worked on a range of applied epidemiological analyses after completing the MSc in Medical Statistics at the London School of Hygiene & Tropical Medicine (LSHTM) in 2016. His PhD used mathematical modelling to synthesise evidence from multiple data sources to infer transmission dynamics of mosquito-borne infectious diseases. He then worked as a postdoctoral researcher at LSHTM in the Electronic Health Records research group using large routinely collected data from general practice and hospitals in the UK to analyse the impact of COVID lockdowns on primacry care and the epidemiology of inflammatory skin diseases and long COVID.

Research interests

Research groups

Publications

List by: Type | Date

Jump to: 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018
Number of items: 39.

2025

Docherty, K. et al. (2025) Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure. European Heart Journal, (doi: 10.1093/eurheartj/ehaf675) (In Press)

Yang, M. et al. (2025) Sacubitril/valsartan and quality of life assessed using the EuroQol 5-Dimension 3-Level Questionnaire Level Sum Score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF. European Heart Journal, (doi: 10.1093/ehjcvp/pvaf064) (PMID:40839760) (Early Online Publication)

Glen, C. et al. (2025) Prospective evaluation of the cardiovascular effects of BRAF and MEK inhibitors in patients with melanoma. JACC: CardioOncology, (Accepted for Publication)

Docherty, K. F. et al. (2025) The estimated benefit of the early initiation. European Heart Journal, (Accepted for Publication)

Chimura, M. et al. (2025) Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS ‐ HF trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3682) (PMID:40377177) (Early Online Publication)

Chimura, M. et al. (2025) Comprehensive analysis of the effects of sacubitril/valsartan according to sex among patients with heart failure and reduced ejection fraction in PARADIGM‐HF. Journal of the American Heart Association, 14(9), e038249. (doi: 10.1161/JAHA.124.038249) (PMID:40265590)

Pabon, M. A. et al. (2025) Finerenone reduces new-onset atrial fibrillation across the spectrum of cardio-kidney-metabolic syndrome: the FINE-HEART pooled analysis. Journal of the American College of Cardiology, 85(17), pp. 1649-1660. (doi: 10.1016/j.jacc.2025.03.429) (PMID:40306837)

Gupta, S. D. et al. (2025) Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF. European Journal of Heart Failure, 27(5), pp. 779-787. (doi: 10.1002/ejhf.3515) (PMID:39563094)

Kondo, T. et al. (2025) The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS ‐ HF. European Journal of Heart Failure, (doi: 10.1002/ejhf.3669) (PMID:40300840) (Early Online Publication)

Butt, J. H. et al. (2025) Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3661) (PMID:40222820) (Early Online Publication)

Butt, J. H. et al. (2025) Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS ‐ HF trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3649) (PMID:40211489) (Early Online Publication)

Broglio, Kristine, Ran, Di, Zhang, Fanni, Henderson, Alasdair ORCID logoORCID: https://orcid.org/0000-0002-8903-4906 and Shahsavari, Sima (2025) Relative performance of frequentist and bayesian methods for incorporating external controls: a case study with patient level data from the DapaHF trial. Statistics in Biopharmaceutical Research, (doi: 10.1080/19466315.2025.2455178) (Early Online Publication)

Butt, J. H. et al. (2025) Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial. Lancet Diabetes and Endocrinology, 13(2), pp. 107-118. (doi: 10.1016/S2213-8587(24)00309-7) (PMID:39818225)

Rankin, S. et al. (2025) Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients. Clinical Science, 139(1), pp. 29-41. (doi: 10.1042/CS20241529) (PMID:39680089)

Vaduganathan, M. et al. (2025) Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure. Circulation, 151(2), pp. 149-158. (doi: 10.1161/CIRCULATIONAHA.124.072055) (PMID:39340828) (PMCID:PMC11732259)

Docherty, K. F. et al. (2025) Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial. Circulation, 151(1), pp. 45-58. (doi: 10.1161/CIRCULATIONAHA.124.072011) (PMID:39342512) (PMCID:PMC11670913)

Matsumoto, S. et al. (2025) Beta‐blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure, 27(1), pp. 124-139. (doi: 10.1002/ejhf.3383) (PMID:39215677)

2024

Vaduganathan, M. et al. (2024) Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nature Medicine, 30(12), pp. 3758-3764. (doi: 10.1038/s41591-024-03264-4) (PMID:39218030) (PMCID:PMC11645272)

Kondo, Toru, Henderson, Alasdair D. ORCID logoORCID: https://orcid.org/0000-0002-8903-4906, Docherty, Kieran F. ORCID logoORCID: https://orcid.org/0000-0002-5446-9969, Jhund, Pardeep S. ORCID logoORCID: https://orcid.org/0000-0003-4306-5317, Vaduganathan, Muthiah, Solomon, Scott D. and McMurray, John J.V. ORCID logoORCID: https://orcid.org/0000-0002-6317-3975 (2024) Why have we not been able to demonstrate reduced mortality in patients with HFmrEF/HFpEF? Journal of the American College of Cardiology, 84(22), pp. 2233-2240. (doi: 10.1016/j.jacc.2024.08.033) (PMID:39217560)

Chimura, M. et al. (2024) Finerenone improves outcomes in patients with heart failure with mildly reduced or preserved ejection fraction irrespective of age: a prespecified analysis of FINEARTS-HF. Circulation: Heart Failure, 17(11), e012437. (doi: 10.1161/CIRCHEARTFAILURE.124.012437) (PMID:39342655) (PMCID:PMC11573060)

Costello, R. E. et al. (2024) Impacts of the COVID-19 pandemic on deprivation-level differences in cardiovascular hospitalisations: a comparison of England and Denmark using the OpenSAFELY platform and National Registry Data. BMJ Open, 14(10), e088710. (doi: 10.1136/bmjopen-2024-088710) (PMID:39414266) (PMCID:PMC11481132)

Jhund, P. S. et al. (2024) Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet, 404(10458), pp. 1119-1131. (doi: 10.1016/S0140-6736(24)01733-1) (PMID:39232490)

Solomon, S. D. et al. (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine, (doi: 10.1056/nejmoa2407107) (PMID:39225278)

Matthewman, J. et al. (2024) Disagreement concerning atopic dermatitis subtypes between an English prospective cohort (ALSPAC) and linked electronic health records. Clinical and Experimental Dermatology, 49(12), pp. 1537-1546. (doi: 10.1093/ced/llae196) (PMID:38751343) (PMCID:PMC11583923)

Matsumoto, S. et al. (2024) Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function. Journal of the American College of Cardiology, 83(24), pp. 2426-2436. (doi: 10.1016/j.jacc.2024.03.426) (PMID:38739064)

Rankin, S. et al. (2024) Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using 18F-FDG positron emission tomography. bioRxiv, (doi: 10.1101/2024.05.30.596741)

Henderson, A. D. et al. (2024) Clinical coding of long COVID in primary care 2020–2023 in a cohort of 19 million adults: an OpenSAFELY analysis. eClinicalMedicine, 72, 102638. (doi: 10.1016/j.eclinm.2024.102638) (PMID:38800803) (PMCID:PMC11127160)

Carlile, O. et al. (2024) The impact of Long COVID on Health-Related Quality-of-Life using OpenPROMPT. Lancet Regional Health - Europe, 40, 100908. (doi: 10.1016/j.lanepe.2024.100908) (PMID:38689605) (PMCID:PMC11059448)

Matsumoto, S. et al. (2024) Effects of sacubitril/valsartan according to polypharmacy status in PARAGON‐HF. European Journal of Heart Failure, 26(5), pp. 1125-1138. (doi: 10.1002/ejhf.3223) (PMID:38587090)

2023

Henderson, A. D. et al. (2023) Cohort profile: OpenPROMPT. medRxiv, (doi: 10.1101/2023.12.21.23300369)

Lin, L.-Y. et al. (2023) Healthcare utilisation in people with long COVID: an OpenSAFELY cohort study. medRxiv, (doi: 10.1101/2023.12.21.23300305)

Henderson, Alasdair D. ORCID logoORCID: https://orcid.org/0000-0002-8903-4906, Adesanya, Elizabeth, Mulick, Amy, Matthewman, Julian, Vu, Nhung, Davies, Firoza, Smith, Catherine H., Hayes, Joseph, Mansfield, Kathryn E. and M. Langan, Sinéad (2023) Common mental health disorders in adults with inflammatory skin conditions: nationwide population-based matched cohort studies in the UK. BMC Medicine, 21(1), 285. (doi: 10.1186/s12916-023-02948-x) (PMID:37542272) (PMCID:PMC10403838)

Bechman, Katie, Hayes, Joseph F., Mathewman, Julian, Henderson, Alasdair D. ORCID logoORCID: https://orcid.org/0000-0002-8903-4906, Adesanya, Elizabeth I., Mansfield, Kathryn E., Smith, Catherine H., Galloway, James and M. Langan, Sinéad (2023) Electronic screening for mental illness in patients with psoriasis. British Journal of Dermatology, 189(2), p. 246. (doi: 10.1093/bjd/ljad141) (PMID:37224480) (PMCID:PMC10351398)

Adesanya, Elizabeth I., Matthewman, Julian, Schonmann, Yochai, Hayes, Joseph F., Henderson, Alasdair ORCID logoORCID: https://orcid.org/0000-0002-8903-4906, Mathur, Rohini, Mulick, Amy R., Smith, Catherine H., M. Langan, Sinéad and Mansfield, Kathryn E. (2023) Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis. British Journal of Dermatology, 188(4), pp. 460-470. (doi: 10.1093/bjd/ljac132) (PMID:36745557)

2021

Mansfield, K. E. et al. (2021) Indirect acute effects of the COVID-19 pandemic on physical and mental health in the UK: a population-based study. Lancet Digital Health, 3(4), e217-e230. (doi: 10.1016/s2589-7500(21)00017-0) (PMID:33612430) (PMCID:PMC7985613)

Henderson, A. D. et al. (2021) Interactions between timing and transmissibility explain diverse flavivirus dynamics in Fiji. Nature Communications, 12, 1671. (doi: 10.1038/s41467-021-21788-y) (PMID:33723237) (PMCID:PMC7961049)

2020

Henderson, A. D. et al. (2020) Zika seroprevalence declines and neutralizing antibodies wane in adults following outbreaks in French Polynesia and Fiji. eLife, 9, e48460. (doi: 10.7554/eLife.48460) (PMID:31987069) (PMCID:PMC6986872)

2019

Henderson, Alasdair ORCID logoORCID: https://orcid.org/0000-0002-8903-4906, Iwagami, Masao, Bottomley, Christian, Tomlinson, Laurie, Mansfield, Kathryn and Nitsch, Dorothea (2019) Paediatric acute kidney injury hospital admissions in England 1997–2014: burden and risk factors. Clinical Kidney Journal, 12(6), pp. 859-860. (doi: 10.1093/ckj/sfz075) (PMID:31807300) (PMCID:PMC6885679)

2018

Kucharski, A.J. et al. (2018) Using paired serology and surveillance data to quantify dengue transmission and control during a large outbreak in Fiji. eLife, 7, e34848. (doi: 10.7554/eLife.34848) (PMID:30103854) (PMCID:PMC6092126)

This list was generated on Sat Sep 6 18:18:52 2025 BST.
Jump to: Articles
Number of items: 39.

Articles

Docherty, K. et al. (2025) Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure. European Heart Journal, (doi: 10.1093/eurheartj/ehaf675) (In Press)

Yang, M. et al. (2025) Sacubitril/valsartan and quality of life assessed using the EuroQol 5-Dimension 3-Level Questionnaire Level Sum Score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF. European Heart Journal, (doi: 10.1093/ehjcvp/pvaf064) (PMID:40839760) (Early Online Publication)

Glen, C. et al. (2025) Prospective evaluation of the cardiovascular effects of BRAF and MEK inhibitors in patients with melanoma. JACC: CardioOncology, (Accepted for Publication)

Docherty, K. F. et al. (2025) The estimated benefit of the early initiation. European Heart Journal, (Accepted for Publication)

Chimura, M. et al. (2025) Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS ‐ HF trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3682) (PMID:40377177) (Early Online Publication)

Chimura, M. et al. (2025) Comprehensive analysis of the effects of sacubitril/valsartan according to sex among patients with heart failure and reduced ejection fraction in PARADIGM‐HF. Journal of the American Heart Association, 14(9), e038249. (doi: 10.1161/JAHA.124.038249) (PMID:40265590)

Pabon, M. A. et al. (2025) Finerenone reduces new-onset atrial fibrillation across the spectrum of cardio-kidney-metabolic syndrome: the FINE-HEART pooled analysis. Journal of the American College of Cardiology, 85(17), pp. 1649-1660. (doi: 10.1016/j.jacc.2025.03.429) (PMID:40306837)

Gupta, S. D. et al. (2025) Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF. European Journal of Heart Failure, 27(5), pp. 779-787. (doi: 10.1002/ejhf.3515) (PMID:39563094)

Kondo, T. et al. (2025) The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS ‐ HF. European Journal of Heart Failure, (doi: 10.1002/ejhf.3669) (PMID:40300840) (Early Online Publication)

Butt, J. H. et al. (2025) Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3661) (PMID:40222820) (Early Online Publication)

Butt, J. H. et al. (2025) Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS ‐ HF trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3649) (PMID:40211489) (Early Online Publication)

Broglio, Kristine, Ran, Di, Zhang, Fanni, Henderson, Alasdair ORCID logoORCID: https://orcid.org/0000-0002-8903-4906 and Shahsavari, Sima (2025) Relative performance of frequentist and bayesian methods for incorporating external controls: a case study with patient level data from the DapaHF trial. Statistics in Biopharmaceutical Research, (doi: 10.1080/19466315.2025.2455178) (Early Online Publication)

Butt, J. H. et al. (2025) Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial. Lancet Diabetes and Endocrinology, 13(2), pp. 107-118. (doi: 10.1016/S2213-8587(24)00309-7) (PMID:39818225)

Rankin, S. et al. (2025) Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients. Clinical Science, 139(1), pp. 29-41. (doi: 10.1042/CS20241529) (PMID:39680089)

Vaduganathan, M. et al. (2025) Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure. Circulation, 151(2), pp. 149-158. (doi: 10.1161/CIRCULATIONAHA.124.072055) (PMID:39340828) (PMCID:PMC11732259)

Docherty, K. F. et al. (2025) Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial. Circulation, 151(1), pp. 45-58. (doi: 10.1161/CIRCULATIONAHA.124.072011) (PMID:39342512) (PMCID:PMC11670913)

Matsumoto, S. et al. (2025) Beta‐blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure, 27(1), pp. 124-139. (doi: 10.1002/ejhf.3383) (PMID:39215677)

Vaduganathan, M. et al. (2024) Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nature Medicine, 30(12), pp. 3758-3764. (doi: 10.1038/s41591-024-03264-4) (PMID:39218030) (PMCID:PMC11645272)

Kondo, Toru, Henderson, Alasdair D. ORCID logoORCID: https://orcid.org/0000-0002-8903-4906, Docherty, Kieran F. ORCID logoORCID: https://orcid.org/0000-0002-5446-9969, Jhund, Pardeep S. ORCID logoORCID: https://orcid.org/0000-0003-4306-5317, Vaduganathan, Muthiah, Solomon, Scott D. and McMurray, John J.V. ORCID logoORCID: https://orcid.org/0000-0002-6317-3975 (2024) Why have we not been able to demonstrate reduced mortality in patients with HFmrEF/HFpEF? Journal of the American College of Cardiology, 84(22), pp. 2233-2240. (doi: 10.1016/j.jacc.2024.08.033) (PMID:39217560)

Chimura, M. et al. (2024) Finerenone improves outcomes in patients with heart failure with mildly reduced or preserved ejection fraction irrespective of age: a prespecified analysis of FINEARTS-HF. Circulation: Heart Failure, 17(11), e012437. (doi: 10.1161/CIRCHEARTFAILURE.124.012437) (PMID:39342655) (PMCID:PMC11573060)

Costello, R. E. et al. (2024) Impacts of the COVID-19 pandemic on deprivation-level differences in cardiovascular hospitalisations: a comparison of England and Denmark using the OpenSAFELY platform and National Registry Data. BMJ Open, 14(10), e088710. (doi: 10.1136/bmjopen-2024-088710) (PMID:39414266) (PMCID:PMC11481132)

Jhund, P. S. et al. (2024) Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet, 404(10458), pp. 1119-1131. (doi: 10.1016/S0140-6736(24)01733-1) (PMID:39232490)

Solomon, S. D. et al. (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine, (doi: 10.1056/nejmoa2407107) (PMID:39225278)

Matthewman, J. et al. (2024) Disagreement concerning atopic dermatitis subtypes between an English prospective cohort (ALSPAC) and linked electronic health records. Clinical and Experimental Dermatology, 49(12), pp. 1537-1546. (doi: 10.1093/ced/llae196) (PMID:38751343) (PMCID:PMC11583923)

Matsumoto, S. et al. (2024) Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function. Journal of the American College of Cardiology, 83(24), pp. 2426-2436. (doi: 10.1016/j.jacc.2024.03.426) (PMID:38739064)

Rankin, S. et al. (2024) Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using 18F-FDG positron emission tomography. bioRxiv, (doi: 10.1101/2024.05.30.596741)

Henderson, A. D. et al. (2024) Clinical coding of long COVID in primary care 2020–2023 in a cohort of 19 million adults: an OpenSAFELY analysis. eClinicalMedicine, 72, 102638. (doi: 10.1016/j.eclinm.2024.102638) (PMID:38800803) (PMCID:PMC11127160)

Carlile, O. et al. (2024) The impact of Long COVID on Health-Related Quality-of-Life using OpenPROMPT. Lancet Regional Health - Europe, 40, 100908. (doi: 10.1016/j.lanepe.2024.100908) (PMID:38689605) (PMCID:PMC11059448)

Matsumoto, S. et al. (2024) Effects of sacubitril/valsartan according to polypharmacy status in PARAGON‐HF. European Journal of Heart Failure, 26(5), pp. 1125-1138. (doi: 10.1002/ejhf.3223) (PMID:38587090)

Henderson, A. D. et al. (2023) Cohort profile: OpenPROMPT. medRxiv, (doi: 10.1101/2023.12.21.23300369)

Lin, L.-Y. et al. (2023) Healthcare utilisation in people with long COVID: an OpenSAFELY cohort study. medRxiv, (doi: 10.1101/2023.12.21.23300305)

Henderson, Alasdair D. ORCID logoORCID: https://orcid.org/0000-0002-8903-4906, Adesanya, Elizabeth, Mulick, Amy, Matthewman, Julian, Vu, Nhung, Davies, Firoza, Smith, Catherine H., Hayes, Joseph, Mansfield, Kathryn E. and M. Langan, Sinéad (2023) Common mental health disorders in adults with inflammatory skin conditions: nationwide population-based matched cohort studies in the UK. BMC Medicine, 21(1), 285. (doi: 10.1186/s12916-023-02948-x) (PMID:37542272) (PMCID:PMC10403838)

Bechman, Katie, Hayes, Joseph F., Mathewman, Julian, Henderson, Alasdair D. ORCID logoORCID: https://orcid.org/0000-0002-8903-4906, Adesanya, Elizabeth I., Mansfield, Kathryn E., Smith, Catherine H., Galloway, James and M. Langan, Sinéad (2023) Electronic screening for mental illness in patients with psoriasis. British Journal of Dermatology, 189(2), p. 246. (doi: 10.1093/bjd/ljad141) (PMID:37224480) (PMCID:PMC10351398)

Adesanya, Elizabeth I., Matthewman, Julian, Schonmann, Yochai, Hayes, Joseph F., Henderson, Alasdair ORCID logoORCID: https://orcid.org/0000-0002-8903-4906, Mathur, Rohini, Mulick, Amy R., Smith, Catherine H., M. Langan, Sinéad and Mansfield, Kathryn E. (2023) Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis. British Journal of Dermatology, 188(4), pp. 460-470. (doi: 10.1093/bjd/ljac132) (PMID:36745557)

Mansfield, K. E. et al. (2021) Indirect acute effects of the COVID-19 pandemic on physical and mental health in the UK: a population-based study. Lancet Digital Health, 3(4), e217-e230. (doi: 10.1016/s2589-7500(21)00017-0) (PMID:33612430) (PMCID:PMC7985613)

Henderson, A. D. et al. (2021) Interactions between timing and transmissibility explain diverse flavivirus dynamics in Fiji. Nature Communications, 12, 1671. (doi: 10.1038/s41467-021-21788-y) (PMID:33723237) (PMCID:PMC7961049)

Henderson, A. D. et al. (2020) Zika seroprevalence declines and neutralizing antibodies wane in adults following outbreaks in French Polynesia and Fiji. eLife, 9, e48460. (doi: 10.7554/eLife.48460) (PMID:31987069) (PMCID:PMC6986872)

Henderson, Alasdair ORCID logoORCID: https://orcid.org/0000-0002-8903-4906, Iwagami, Masao, Bottomley, Christian, Tomlinson, Laurie, Mansfield, Kathryn and Nitsch, Dorothea (2019) Paediatric acute kidney injury hospital admissions in England 1997–2014: burden and risk factors. Clinical Kidney Journal, 12(6), pp. 859-860. (doi: 10.1093/ckj/sfz075) (PMID:31807300) (PMCID:PMC6885679)

Kucharski, A.J. et al. (2018) Using paired serology and surveillance data to quantify dengue transmission and control during a large outbreak in Fiji. eLife, 7, e34848. (doi: 10.7554/eLife.34848) (PMID:30103854) (PMCID:PMC6092126)

This list was generated on Sat Sep 6 18:18:52 2025 BST.

Prior publications

Article

Kieran F. Docherty, Alasdair D. Henderson, Pardeep S. Jhund, Scott D. Solomon, John J.V. McMurray (2025) Response by Docherty et al to Letter Regarding Article, “Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial” Circulation Crossref. (doi: 10.1161/CIRCULATIONAHA.125.075278)

Adesanya, E.I., Henderson, A., Hayes, J.F., Lewin, A., Mathur, R., Mulick, A., Morton, C., Smith, C., Langan, S.M., Mansfield, K.E. (2024) Ethnic differences in depression and anxiety among adults with atopic eczema: Population-based matched cohort studies within UK primary care Clinical and Translational Allergy Scopus - Elsevier. ISSN 20457022 (doi: 10.1002/clt2.12348)

Matthewman, J., Mansfield, K.E., Hayes, J.F., Adesanya, E.I., Smith, C.H., Roberts, A., Langan, S.M., Henderson, A.D. (2023) Anxiety and Depression in People with Eczema or Psoriasis: A Comparison of Associations in UK Biobank and Linked Primary Care Data Clinical Epidemiology Scopus - Elsevier. ISSN 11791349 (doi: 10.2147/CLEP.S417176)

Matthewman, J. et al. (2023) Association of Different Prescribing Patterns for Oral Corticosteroids with Fracture Preventive Care among Older Adults in the UK and Ontario JAMA Dermatology Scopus - Elsevier. ISSN 21686084 21686068 (doi: 10.1001/jamadermatol.2023.2495)

Adesanya, E.I. et al. (2023) Severe Mental Illness Among Adults with Atopic Eczema or Psoriasis: Population-Based Matched Cohort Studies within UK Primary Care Clinical Epidemiology Scopus - Elsevier. ISSN 11791349 (doi: 10.2147/CLEP.S384605)

Aubry, M. et al. (2020) Low chikungunya virus seroprevalence two years after emergence in Fiji International Journal of Infectious Diseases Scopus - Elsevier. ISSN 18783511 12019712 (doi: 10.1016/j.ijid.2019.10.040)

Other

Costello, R.E. et al. (2023) Ethnic differences in the indirect impacts of the COVID-19 pandemic on clinical monitoring and hospitalisations for non-COVID conditions in England: An observational cohort study using OpenSAFELY medRxiv Scopus - Elsevier. (doi: 10.1101/2023.01.04.23284174)

Mansfield, K.E. et al. (2020) COVID-19 Collateral: Indirect Acute Effects of the Pandemic on Physical and Mental Health in the UK SSRN Scopus - Elsevier. ISSN 15565068 (doi: 10.2139/ssrn.3719882)

Henderson, A.D. et al. (2019) Zika virus seroprevalence declines and neutralization antibodies wane in adults following outbreaks in French Polynesia and Fiji bioRxiv Scopus - Elsevier. ISSN 26928205 (doi: 10.1101/578211)